var data={"title":"Methoxy polyethylene glycol-epoetin beta: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Methoxy polyethylene glycol-epoetin beta: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/540330?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=methoxy-polyethylene-glycol-epoetin-beta-patient-drug-information\" class=\"drug drug_patient\">see &quot;Methoxy polyethylene glycol-epoetin beta: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28331077\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Chronic kidney disease:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL. No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks. Use the lowest dose sufficient to reduce the need for red blood cell (RBC) transfusions.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cancer:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Methoxy polyethylene glycol-epoetin beta is not indicated and is not recommended for the treatment of anemia due to cancer chemotherapy. A dose-ranging study was terminated early because of more deaths among patients receiving methoxy polyethylene glycol-epoetin beta than another ESA. ESAs have shown shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28623608\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Mircera</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28331079\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Colony Stimulating Factor;</li>\n      <li>\n        Erythropoiesis-Stimulating Agent (ESA);</li>\n      <li>\n        Hematopoietic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28623487\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Evaluate iron status before and during treatment and maintain iron repletion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Anemia associated with chronic kidney disease (CKD):</b> Individualize dosing and use the lowest dose necessary to reduce the need for RBC transfusions:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Patients not currently taking an ESA:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Chronic kidney disease patients on dialysis (IV route is preferred for hemodialysis patients; initiate treatment when hemoglobin &lt;10 g/dL):</i> Initial: IV, SubQ: 0.6 mcg/kg once every 2 weeks. Reduce dose or interrupt treatment if hemoglobin approaches or exceeds 11 g/dL. After hemoglobin stabilizes, may administer once monthly with a dose that is double the dose administered every 2 weeks; titrate as necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Chronic kidney disease patients <b>NOT</b> on dialysis (consider initiating treatment when hemoglobin &lt;10 g/dL and the rate of hemoglobin decline would likely result in RBC transfusion and goal is to reduce risk of alloimmunization or other RBC transfusion-related risks):</i> Initial: IV, SubQ: 0.6 mcg/kg once every 2 weeks. Reduce dose or interrupt treatment if hemoglobin exceeds 10 g/dL. After hemoglobin stabilizes, may administer once monthly with a dose that is double the dose administered every 2 weeks; titrate as necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Patients converting from epoetin alfa or darbepoetin alfa:</b> IV, SubQ: Based on total weekly ESA dose at the time of conversion (if hemoglobin is stabilized):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For epoetin alfa dose &lt;8,000 units/week or darbepoetin alfa dose &lt;40 mcg/week: Administer methoxy polyethylene glycol-epoetin beta 120 mcg once monthly or 60 mcg every 2 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For epoetin alfa dose 8,000 to 16,000 units/week or darbepoetin alfa dose 40 to 80 mcg/week: Administer methoxy polyethylene glycol-epoetin beta 200 mcg once monthly or 100 mcg every 2 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For epoetin alfa dose &gt;16,000 units/week or darbepoetin alfa dose &gt;80 mcg/week: Administer methoxy polyethylene glycol-epoetin beta 360 mcg once monthly or 180 mcg every 2 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dosage adjustments for all CKD patients:</i> Do not increase dose more frequently than every 4 weeks (dose decreases may occur more often); avoid frequent dosage adjustments.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If hemoglobin increases &gt;1 g/dL in any 2-week period: Decrease dose by &ge;25% as needed to reduce rapid responses.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If hemoglobin does not increase by &gt;1 g/dL after 4 weeks of therapy: Increase dose by 25%.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Inadequate or lack of response over 12 weeks of therapy: If adequate response is not achieved after 12 weeks of therapy, further increases are unlikely to be of benefit and may increase the risk for adverse events; use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid red blood cell transfusions <b>and</b> evaluate patient for other causes of anemia. Discontinue treatment if responsiveness does not improve.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28623491\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing; initiate at the lower end of dosing ranges.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28623492\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided  in the manufacturer&rsquo;s labeling; however, methoxy polyethylene glycol-epoetin beta is indicated for use in patients with chronic kidney disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28623493\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28623494\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serious allergic/anaphylactic reactions: Discontinue immediately (and permanently).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypertension (difficult to control): Reduce dose or withhold treatment (use is contraindicated in uncontrolled hypertension).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pure red cell aplasia (PRCA): Permanently discontinue treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29032096\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mircera: 50 mcg/0.3 mL (0.3 mL); 75 mcg/0.3 mL (0.3 mL); 100 mcg/0.3 mL (0.3 mL); 200 mcg/0.3 mL (0.3 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mircera: 30 mcg/0.3 mL (0.3 mL); 50 mcg/0.3 mL (0.3 mL); 75 mcg/0.3 mL (0.3 mL); 100 mcg/0.3 mL (0.3 mL); 150 mcg/0.3 mL (0.3 mL); 200 mcg/0.3 mL (0.3 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29032095\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28620359\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Distribution is restricted to certain dialysis centers.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28620356\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088644.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlfSycXv1yAGEM96d6p/9RIA==&amp;TOPIC_ID=101636\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088644.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28623496\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer intravenously (IV) or subcutaneously (SubQ).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">For administration using the prefilled syringe, the plunger must be fully depressed during injection to activate the needle guard. Following administration, remove the needle from the injection site and release the plunger to allow the needle guard to move up until the entire needle is covered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: Inject in the abdomen, arm, or thigh.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28331081\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anemia: </b>Treatment of anemia associated with chronic kidney disease (CKD) in adult patients  on dialysis and patients not on dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Not indicated and is not recommended in the treatment of anemia due to cancer chemotherapy or as a substitute for red blood cell (RBC) transfusions in patients who require immediate correction of anemia; has not been shown to improve symptoms, physical functioning or health-related quality of life. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28620355\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Methoxy polyethylene glycol-epoetin beta may be confused with darbepoetin alfa, epoetin alfa</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Mircera may be confused with Mirena</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F30159646\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Exacerbation of hypertension (27%), hypertension (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Procedural hypotension (8%), arteriovenous fistula site complication (5%), hypotension (5%), thrombosis (5%; arteriovenous fistula)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypervolemia (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (6%), constipation (5%), gastrointestinal hemorrhage (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hemorrhage (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Muscle spasm (8%), back pain (6%), limb pain (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (9%), cough (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, bronchospasm, hypertensive encephalopathy, pruritus, pure red cell aplasia, seizure, severe anemia, skin rash, Stevens-Johnson syndrome, tachycardia, toxic epidermal necrolysis, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28331082\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Severe hypersensitivity to methoxy polyethylene glycol-epoetin beta (eg, anaphylactic reactions, angioedema, bronchospasm, skin rash, and urticaria); pure red cell aplasia (PRCA) that begins after treatment with methoxy polyethylene glycol-epoetin beta or other erythropoietin protein drugs; uncontrolled hypertension</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28620361\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Allergic reactions: Serious allergic reactions (including anaphylactic reactions angioedema, bronchospasm, tachycardia, pruritus, rash, and urticaria) have been reported. Discontinue immediately (and permanently) in patients who experience serious allergic/anaphylactic reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events: In controlled studies of patients with chronic kidney disease (CKD) comparing higher hemoglobin targets (13 to 14 g/dL) to lower targets (9 to 11.3 g/dL), erythropoiesis-stimulating agents (ESAs) increased the risk of death, MI, stroke, heart failure, hemodialysis vascular access thrombosis, and other thromboembolic events in the higher hemoglobin target groups. Using ESAs to target a hemoglobin &gt;11 g/dL does not demonstrate additional benefit and may also contribute to these risks. Use with caution in patient with a current or a history of cardiovascular disease and stroke. A rate of hemoglobin rise of &gt;1 g/dL over 2 weeks may also contribute to cardiovascular risks. In controlled studies of patients with cancer, ESAs increased the risk of death and cardiovascular reactions (including MI and stroke). Patients with cancer treated with ESAs have in increased incidence of thromboembolic events; may be serious or life-threatening. In controlled studies, ESAs increased the risk of death in patients undergoing coronary artery bypass graft (CABG) surgery and increased the risk of deep venous thrombosis (DVT) in patients undergoing orthopedic procedures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: In studies of methoxy polyethylene glycol-epoetin beta in patients with CKD, intensification of antihypertensive therapy was required in over one-fourth of patients.  Hypertensive encephalopathy and/or seizures have been reported. Blood pressure should be controlled prior to treatment initiation and during therapy. Reduce or withhold treatment if blood pressure becomes difficult to control. Use is contraindicated in uncontrolled hypertension. Patients should comply with antihypertensive therapy and dietary restrictions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pure red cell aplasia (PRCA): Although not observed in clinical studies, postmarketing cases of severe anemia and PRCA (with or without other cytopenias) have been reported with methoxy polyethylene glycol-epoetin beta, arising following the development of neutralizing antibodies to erythropoietin. PRCA reports associated with ESAs have been predominantly in patients with CKD receiving subQ administration. Cases have also been reported in patients with hepatitis C who were receiving ESAs for anemia. Withhold the dose and evaluate for neutralizing antibodies to erythropoietin in patients with severe anemia and a low reticulocyte count during treatment (obtain serum samples at least a month after the last dose to prevent assay interference). Discontinue treatment (permanently) in patients who develop PRCA (to any ESA); antibodies may cross-react; do not switch to another ESA.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Seizures have been observed in studies with methoxy polyethylene glycol-epoetin beta. Monitor closely for premonitory neurologic symptoms during the first several months after treatment initiation. Patients should be advised to contact health care provider if seizures occur (new -onset or change in frequency), orf for premonitory symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cancer:<b> [US Boxed Warning]: Methoxy polyethylene glycol-epoetin beta is not indicated and is not recommended for the treatment of anemia due to cancer chemotherapy. A dose-ranging study was terminated early due to increased deaths among patients receiving methoxy polyethylene glycol-epoetin beta than another ESA. ESAs have demonstrated shortened overall survival and/or increased the risk of tumor progression or recurrence in studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers.</b> Methoxy polyethylene glycol-epoetin beta is <b>not</b> approved and is not recommend for use in the treatment of anemia due to cancer chemotherapy. ESA use is associated with decreased locoregional control, progression free survival and/or overall survival.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic kidney disease: <b>[US Boxed Warning]: In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of &gt;11 g/dL. No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks. Use the lowest dose sufficient to reduce the need for red blood cell (RBC) transfusions.</b> Evaluate the benefit of decreasing transfusions against the risk of death or other serious cardiovascular events.  May reduce dialysis efficacy (due to increase in red blood cells and decrease in plasma volume); adjustments in dialysis parameters may be needed. Patients may require increased heparinization during dialysis to prevent clotting of the extracorporeal circuit.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Perisurgical patients: Methoxy polyethylene glycol-epoetin beta is not approved for reduction in allogeneic red blood cell transfusions in patients scheduled for surgical procedures. An increased incidence of DVT has been observed in patients treated with epoetin alfa undergoing surgical orthopedic procedures. Increased mortality was observed in patients undergoing coronary artery bypass surgery who received epoetin alfa.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Evaluate iron status (eg, transferrin saturation and serum ferritin) prior to and during treatment; maintain iron repletion. Correct (or exclude) other causes of anemia (eg, vitamin deficiency, metabolic or chronic inflammatory conditions, bleeding) prior to treatment initiation. When adjusting therapy, consider rate of hemoglobin change, ESA responsiveness, and hemoglobin variability; a single hemoglobin level excursion may not require dosage alteration. For lack or loss of hemoglobin response, evaluate patient for causative factors (eg, iron deficiency, infection, inflammation, bleeding); if typical causes are excluded, evaluate for PRCA. If PRCA is excluded, follow dosing recommendation for insufficient response.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407212\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28407209\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=101636&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Lenalidomide: Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Lenalidomide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nandrolone: May enhance the stimulatory effect of Erythropoiesis-Stimulating Agents. Specifically, nandrolone may enhance the erythropoiesis stimulatory effect of Erythropoiesis-Stimulating Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pomalidomide: Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Pomalidomide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Thalidomide. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28623501\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28623502\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28623504\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if methoxy polyethylene glycol-epoetin beta is excreted in breast milk. The manufacturer recommends that caution be used if administered to a nursing woman.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28623499\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hemoglobin levels (at least weekly until stable, then at least monthly); iron stores (transferrin saturation and serum ferritin) at baseline and during therapy; premonitory neurologic symptoms of seizures, blood pressure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28621901\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Methoxy polyethylene glycol-epoetin beta is an erythropoietin receptor activator; erythropoietin is a primary growth factor for erythroid development and is produced in the kidney and released into the bloodstream in response to hypoxia. In response to hypoxia, erythropoietin interacts with erythroid progenitor cells to increase red blood cell production.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28621903\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Hemoglobin increase (following a single initial dose): 7 to 15 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: SubQ: 62%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IV: 134 &plusmn; 65 hours; SubQ: 139 &plusmn; 67 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: SubQ: 72 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29835907\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Mircera Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mcg/0.3 ml (0.3 mL): $99.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mcg/0.3 ml (0.3 mL): $108.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mcg/0.3 ml (0.3 mL): $162.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/0.3 ml (0.3 mL): $216.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mcg/0.3 ml (0.3 mL): $495.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg/0.3 ml (0.3 mL): $432.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28753578\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Mircera (AE, AR, AT, AU, BB, BE, BH, BR, CH, CL, CO, CR, CU, CZ, DE, DK, DO, EC, EE, ES, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IN, IS, IT, JO, JP, KR, KW, LB, LK, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, VN, ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Mircera (methoxy polyethylene glycol-epoetin beta) [prescribing information]. South San Francisco, CA: Hoffmann-La Roche Inc; October 2014. </div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 101636 Version 42.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F28331077\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F28623608\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F28331079\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F28623487\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F28623491\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F28623492\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F28623493\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F28623494\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F29032096\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F29032095\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F28620359\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F28620356\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F28623496\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F28331081\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F28620355\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F30159646\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F28331082\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F28620361\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F28407212\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F28407209\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F28623501\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F28623502\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F28623504\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F28623499\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F28621901\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F28621903\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F29835907\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F28753578\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/101636|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=methoxy-polyethylene-glycol-epoetin-beta-patient-drug-information\" class=\"drug drug_patient\">Methoxy polyethylene glycol-epoetin beta: Patient drug information</a></li></ul></div></div>","javascript":null}